RxDoctor Payments Data

Roger Bellamy, PA

Medical · Temecula, CANPI 1699968826

Payments from drug & device makers

$9,129in general payments, 2019–2025

Across 485 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Sanofi$979
  • Johnson & Johnson$775
  • Amgen$612
  • Pfizer$556
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$8,91998%
  • Education$2102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,129 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$181,287
Medicare patients
850
Services billed
3,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab53$408,809
Dupixent PenDupilumab78$283,822
OtezlaApremilast38$184,535
Taltz AutoinjectorIxekizumab26$174,243
Cosentyx Unoready PenSecukinumab12$144,387
RinvoqUpadacitinib15$92,382
Betamethasone Dipropionate327$13,886
Ketoconazole517$8,998
Doxycycline Monohydrate213$4,378
Clobetasol Propionate51$3,292
Tretinoin30$2,516
Triamcinolone Acetonide288$2,135
Fluorouracil21$2,078
Clindamycin Phosphate52$2,018
Calcipotriene15$1,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$612$184,53538 claims
AbbVieRinvoq$2,022$92,38215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →